.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Avexia is stocked at 510 licensed dispensaries across Illinois, New Jersey, and 8 other states, 155 of them in Illinois, with the deepest coverage in Chicago, Springfield, Normal, Quincy, and Schaumburg. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Avexia’s mix in August 2026 is concentrated in Topical at 48.7% share (month-over-month +3.9%, year-over-year -25.1%), with Capsules at 25.4% share (MoM -2.0%, YoY -25.6%) and Concentrates at 18.9% share (MoM +14.8%, YoY -52.2%), while Tincture & Sublingual holds 6.9% share (MoM -14.9%, YoY -52.9%). Despite brand-level sales down 34.9% year-over-year and average price down 6.3% YoY, the category tilt is stabilizing around Topical and a rebound in Concentrates, implying a deliberate pivot toward higher-velocity formats where near-term MoM gains can partially offset double-digit YoY declines.
Holding rank 1 in Topical in Illinois alongside a 48.7% internal mix weight and a +3.9% MoM lift suggests Avexia’s clearest path is deepening leadership in Topical while using Concentrates’ +14.8% MoM as a secondary growth lever despite its -52.2% YoY drag. With Capsules shrinking -2.0% MoM and Tincture & Sublingual falling -14.9% MoM, the pattern points to concentrating assortment and pricing around Topical’s category strength and selectively nurturing Concentrates recovery to improve overall momentum without diluting focus.
Competitive Landscape
Avexia holds #1 in IL Topical in August 2026 with no year-over-year rank change from #1, and no three-month rank movement from #1 either; that stability contrasts with Doctor Solomon's holding at #2 while posting a -32.8% year-over-year sales decline, and Nature's Grace and Wellness remaining #3 alongside a 10.0% year-over-year sales increase, indicating Avexia’s leadership persists even as tier-two brands diverge in momentum. Further down the leaderboard, Alchemy (Ieso) stayed #4 with a -12.8% year-over-year sales change while Alluris Wellness remained #5 with a 15.3% year-over-year lift, reinforcing that Avexia’s unchanged #1 rank and peak position in August 2026 imply entrenchment at the top as competitors trade growth and contraction without dislodging it.
Notable Products
CBD/THC 1:1 Strawberry Orange Cream Tincture (100mg CBD, 100mg THC, 30ml) posted the steepest decline at -19.7% and sits at rank 10, while CBD/THC 4:1 Relief Tablets 40-Pack (400mg CBD, 100mg THC) fell -9.8% at rank 2; this contrast brackets a category split where Tincture & Sublingual has one SKU up 11.6% at rank 9 and another sharply down, implying sensitivity to flavor or dosing formats. At the top, CBD/THC 1:1 Harmony Pain Relief Balm (100mg CBD, 100mg THC, 2oz) grew 72.6% to $217,906 and holds rank 1, while the adjacent CBD/THC 1:1 Harmony Pain Relief Lotion (100mg CBD, 100mg THC, 2oz) rose 9.7% at rank 5; three of the top ten are Topical SKUs, indicating concentration around external relief use-cases. Within Capsules, CBD/THC 1:1 Harmony Micro-Dosed Tablets 40-Pack (100mg CBD,100mg THC) climbed 36.4% to rank 3 as CBN/CBD/THC 1:1:1 Comfort Tablets 40-Pack fell -14.3% at rank 4 and CBG/THC 1:1 Ascend Tablets 40-Pack slipped -8.0% at rank 6; this divergence suggests consumer preference is consolidating around balanced 1:1 dosing over multi-cannabinoid or CBG-led formulas. Overall, the mix tilts toward pain relief and accessible 1:1 formats rather than exploratory cannabinoid blends, signaling that Avexia’s near-term commercial direction is best served by doubling down on core 1:1 Topicals and micro-dosed Tablets while pruning underperforming tincture variants.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
